Market Place
Sourcing Support
All News #Library
Biotech
Denali Regains Full Rights to Investigational Therapy DNL593
03 Apr 2026 //
GLOBENEWSWIRE
Denali Pharma Reveals 2026 Focus: Tividenofusp Alfa Launch
06 Jan 2026 //
GLOBENEWSWIRE
Denali Therapeutics, Royalty Pharma Ink $275M Royalty Deal
06 Dec 2025 //
GLOBENEWSWIRE
Denali Therapeutics Unveils Q3 2025 Financials & Business
06 Nov 2025 //
GLOBENEWSWIRE
Denali Therapeutics Reports Q1 2025 Results and BLA Submission
06 May 2025 //
GLOBENEWSWIRE
Denali Announces Phase 1/2 Analysis for Tividenofusp Alfa in MPS II
06 Feb 2025 //
GLOBENEWSWIRE
Denali To Present Tividenofusp Alfa, Hunter Syndrome Data
30 Jan 2025 //
GLOBENEWSWIRE
Tenvie takes off with $200M, assets and exec from Denali
10 Jan 2025 //
FIERCE BIOTECH
Denali Gain FDA Breakthrough For Tividenofusp In Hunter
08 Jan 2025 //
GLOBENEWSWIRE
Sanofi flunks MS study, dealing another blow to Denali pact
11 Oct 2024 //
FIERCE BIOTECH
Denali Therapeutics Publishes Data On Oligonucleotide Transport Vehicle Platform
14 Aug 2024 //
GLOBENEWSWIRE
Denali Reports New Method To Transport ASOs Across Blood-Brain Barrier
14 Aug 2024 //
FIERCE BIOTECH
Biogen Exits Denali Alzheimer`s Collaboration
01 Aug 2024 //
FIERCE BIOTECH
Denali Announces Expansion of BBB-Crossing Enzyme Replacement Therapy Programs
07 Feb 2024 //
GLOBENEWSWIRE
Denali Announces Robust Reduction in Neurofilament Light (NfL) with DNL310
20 Jun 2023 //
GLOBENEWSWIRE
Denali Announces New DNL343 (eIF2B Agonist) Phase 1b Data in ALS To Be Presented
10 Apr 2023 //
PRESS RELEASE
Denali Announces Data from DNL310 Phase 1/2 Study for MPS II & DNL126
22 Feb 2023 //
GLOBENEWSWIRE
CENTOGENE and Denali Extend Observational Study on Parkinson`s Disease Genetics
09 Jan 2023 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.